Newborn Screening for Severe Combined Immunodeficiency : Analytic and Clinical Performance of the T Cell Receptor Excision Circle Assay in France (DEPISTREC Study)
Severe combined immunodeficiency (SCID) is characterized by a major T cell deficiency. Infants with SCID are asymptomatic at birth but die from infections in the first year of life if not treated. Survival rates are better for early treatment. SCID therefore meets criteria for newborn screening (NBS). T cell receptor excision circle (TREC) quantification is a reliable marker of T cell deficiency and can be performed using Guthrie cards. The DEPISTREC project was designed to study the feasibility, clinical utility, and cost-effectiveness of generalized SCID screening in France. About 200,000 babies from all over the country were screened at birth with a commercial kit. We determined assay performance and proposed a cutoff for classification of results. Our findings suggest that, given clearly established validation rules and decision-making procedures, the TREC assay is a suitably specific and sensitive method for high-throughput SCID screening. Clinical Trials: NCT02244450.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of clinical immunology - 38(2018), 7 vom: 24. Okt., Seite 778-786 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Audrain, Marie A P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.10.2019 Date Revised 15.10.2019 published: Print-Electronic ClinicalTrials.gov: NCT02244450 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10875-018-0550-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288874234 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288874234 | ||
| 003 | DE-627 | ||
| 005 | 20231225061312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10875-018-0550-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0962.xml |
| 035 | |a (DE-627)NLM288874234 | ||
| 035 | |a (NLM)30251145 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Audrain, Marie A P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Newborn Screening for Severe Combined Immunodeficiency |b Analytic and Clinical Performance of the T Cell Receptor Excision Circle Assay in France (DEPISTREC Study) |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2019 | ||
| 500 | |a Date Revised 15.10.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02244450 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe combined immunodeficiency (SCID) is characterized by a major T cell deficiency. Infants with SCID are asymptomatic at birth but die from infections in the first year of life if not treated. Survival rates are better for early treatment. SCID therefore meets criteria for newborn screening (NBS). T cell receptor excision circle (TREC) quantification is a reliable marker of T cell deficiency and can be performed using Guthrie cards. The DEPISTREC project was designed to study the feasibility, clinical utility, and cost-effectiveness of generalized SCID screening in France. About 200,000 babies from all over the country were screened at birth with a commercial kit. We determined assay performance and proposed a cutoff for classification of results. Our findings suggest that, given clearly established validation rules and decision-making procedures, the TREC assay is a suitably specific and sensitive method for high-throughput SCID screening. Clinical Trials: NCT02244450 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Newborn screening | |
| 650 | 4 | |a T cell receptor excision circle (TREC) quantification | |
| 650 | 4 | |a analytic performance | |
| 650 | 4 | |a clinical performance | |
| 650 | 4 | |a severe combined immunodeficiency (SCID) | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Reagent Kits, Diagnostic |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 700 | 1 | |a Léger, Alexandra J C |e verfasserin |4 aut | |
| 700 | 1 | |a Hémont, Caroline A F |e verfasserin |4 aut | |
| 700 | 1 | |a Mirallié, Sophie M |e verfasserin |4 aut | |
| 700 | 1 | |a Cheillan, David |e verfasserin |4 aut | |
| 700 | 1 | |a Rimbert, Marie G M |e verfasserin |4 aut | |
| 700 | 1 | |a Le Thuaut, Aurélie M-P |e verfasserin |4 aut | |
| 700 | 1 | |a Sébille-Rivain, Véronique A |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Aurore |e verfasserin |4 aut | |
| 700 | 1 | |a Pinel, Enora M Q |e verfasserin |4 aut | |
| 700 | 1 | |a Divry, Eléonore |e verfasserin |4 aut | |
| 700 | 1 | |a Dert, Cécile G L |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Maxime A G |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Caroline J C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d 1981 |g 38(2018), 7 vom: 24. Okt., Seite 778-786 |w (DE-627)NLM012677426 |x 1573-2592 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2018 |g number:7 |g day:24 |g month:10 |g pages:778-786 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10875-018-0550-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2018 |e 7 |b 24 |c 10 |h 778-786 | ||